No, it did not. Health Canada based its decision on a number of elements. There was evidence of immunogenicity—that people over 65 in immunogenicity studies were building antibodies when administered this vaccine. The paucity of the data is related to the small number of people who were in clinical trials who were 65 and over, and that's reflected in the product monograph—
On March 11th, 2021. See this statement in context.